Anti-CD44 monoclonal antibodies (mAbs) have been shown to block the formation of subcutaneous tumors and to repress metastasis in mice [32, 33], and down regulation of CD44 in cancer cells has been shown to reduce stem cell-associated traits [34–36]. This evidence concerns the gene CD44 and cancer.